M. Pombo-Suárez

发表

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

K. Pavelka, M. Santos, D. Courvoisier, 2020, Seminars in arthritis and rheumatism.

Differential upregulation of the three transforming growth factor beta isoforms in human osteoarthritic cartilage

M. Calaza, J. Gómez-Reino, M. Pombo-Suarez, 2008, Annals of the rheumatic diseases.

Abatacept for the treatment of rheumatoid arthritis

J. Gómez-Reino, M. Pombo-Suarez, M. Pombo-Suárez, 2019, Expert review of clinical immunology.

The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondylarthritis.

L. Jacobsson, H. Mann, M. Santos, 2022, Rheumatology.

Lack of association of a variable number of aspartic acid residues in the asporin gene with osteoarthritis susceptibility: case-control studies in Spanish Caucasians

J. Gómez-Reino, Antonio González, J. Rodríguez-López, 2006, Arthritis research & therapy.

Genetic risk load and age at symptom onset of knee osteoarthritis

M. Calaza, J. Gómez-Reino, Antonio González, 2012, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

An SNP in the 5′-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage

S. Snelling, L. Southam, J. Gómez-Reino, 2007 .

Association of a nsSNP in ADAMTS14 to some osteoarthritis phenotypes.

T. Spector, P. Slagboom, A. Valdes, 2009, Osteoarthritis and cartilage.

Functional analysis of the osteoarthritis susceptibility-associated GDF5 regulatory polymorphism.

L. Southam, Antonio González, I. Lorenzen, 2009, Arthritis and rheumatism.

Genetic variation including nonsynonymous polymorphisms of a major aggrecanase, ADAMTS-5, in susceptibility to osteoarthritis.

John Loughlin, Konstantinos N Malizos, J. Gómez-Reino, 2008, Arthritis and rheumatism.

Further evidence of the role of frizzled-related protein gene polymorphisms in osteoarthritis

J. Gómez-Reino, Antonio González, J. Gómez-Reino, 2007, Annals of the rheumatic diseases.

An SNP in the 5'-UTR of GDF5 is associated with osteoarthritis susceptibility in Europeans and with in vivo differences in allelic expression in articular cartilage.

John Loughlin, Lorraine Southam, Kay Chapman, 2007, Human molecular genetics.

Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

F. Roemer, S. Ohtori, Robert B. Bolash, 2020, Pain.

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

G. Macfarlane, K. Pavelka, M. Santos, 2020, RMD open.

Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases

J. Gómez-Reino, M. Pombo-Suarez, M. Pombo-Suárez, 2020 .

Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

J. Gómez-Reino, S. Manrique-Arija, J. del Pino-Montes, 2021, Clinical Rheumatology.

Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open‐label, Phase 3b/4 Trial

R. Baron, A. Binder, I. Steigerwald, 2016, Pain practice : the official journal of World Institute of Pain.

One-third of European axial spondyloarthritis patients reach pain"remission" with routine care TNF-inhibitor treatment.

G. Jones, G. Macfarlane, K. Pavelka, 2022, Journal of Rheumatology.

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

B. Leeb, K. Pavelka, M. Santos, 2022, Annals of the Rheumatic Diseases.

Reference genes for normalization of gene expression studies in human osteoarthritic articular cartilage

M. Calaza, J. Gómez-Reino, Antonio González, 2008, BMC Molecular Biology.

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration

L. Jacobsson, M. Santos, Gareth T. Jones, 2021, Annals of the Rheumatic Diseases.

292 A CHANGE OF GLUTAMIC ACID FOR GLICINE IN THE ADAMTS14 PROTEASE ASSOCIATED WITH SUSCEPTIBILITY TO PRIMARY KNEE OSTEOARTHRITIS

J. Gómez-Reino, Antonio González, A. Tsezou, 2007 .

OP0109 CO-MEDICATION WITH A CONVENTIONAL SYNTHETIC DMARD IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS IS ASSOCIATED WITH IMPROVED RETENTION OF TNF INHIBITORS: RESULTS FROM THE EUROSPA COLLABORATION

L. Jacobsson, H. Mann, G. Macfarlane, 2020, Annals of the Rheumatic Diseases.

After JAK inhibitor failure: to cycle or to switch, that is the question – data from the JAK-pot collaboration of registries

B. Leeb, K. Pavelka, D. Courvoisier, 2022, Annals of the Rheumatic Diseases.

Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries

H. Mann, M. Santos, A. Loft, 2021, Arthritis care & research.

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain

J. Gómez-Reino, M. Pombo-Suarez, José Ramón Maneiro Fernández, 2021, Patient preference and adherence.

Adherence to Treatment in Patients with Rheumatoid Arthritis from Spain

J. Gómez-Reino, J. Maneiro, Manuel Pombo-Suarez, 2021 .

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.

K. Pavelka, M. Santos, D. Courvoisier, 2019, Rheumatology.

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries

K. Pavelka, M. Santos, D. Courvoisier, 2018, RMD Open.

SAT0391 REMISSION AND DRUG RETENTION RATES OF SECUKINUMAB IN 1549 PATIENTS WITH PSORIATIC ARTHRITIS TREATED IN ROUTINE CARE – POOLED DATA FROM THE OBSERVATIONAL EUROSPA RESEARCH COLLABORATION NETWORK

L. Jacobsson, H. Mann, K. Pavelka, 2019, Saturday, 15 June 2019.

Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care

B. Gudbjornsson, T. Love, F. Iannone, 2024, The Journal of Rheumatology.

Impact of multimorbidity on the first ts/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry

R. Ortega-Castro, F. Sánchez-Alonso, L. Ladehesa-Pineda, 2024, Arthritis Research & Therapy.

Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

F. Sánchez-Alonso, F. Díaz-González, I. Castrejón, 2023, Advances in Rheumatology.

Practical normalization of mRNA expression in quantitative PCR for cartilage research.

M. Calaza, J. Gómez-Reino, M. Pombo-Suárez, 2009, Osteoarthritis and cartilage.